Product Datasheet

BLAME/SLAMF8 Antibody
NBP2-26110

Unit Size: 0.1 mg

Store at -20C. Avoid freeze-thaw cycles.

www.novusbio.com technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-26110

Updated 9/9/2025 v.20.1



NBP2-26110

BLAME/SLAMF8 Antibody

Product Information

Unit Size	0.1 mg
Concentration	0.5 mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA

Product Description

Description	Novus Biologicals Goat BLAME/SLAMF8 Antibody (NBP2-26110) is a polyclonal antibody validated for use in IHC, WB and ELISA. Anti-BLAME/SLAMF8 Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Goat
Gene ID	56833
Gene Symbol	SLAMF8
Species	Human
Reactivity Notes	Expected from sequence similarity: Mouse, Rat, Bovine
Immunogen	Peptide with sequence C-TLYHSRFLGRAQ corresponding to internal region according to NP_064510.1.

Product Application Details

Applications	Western Blot, Immunohistochemistry-Paraffin, Immunohistochemistry, Peptide ELISA
Recommended Dilutions	Western Blot 1:100 - 1:2000, Immunohistochemistry 0.5-1ug/ml, Immunohistochemistry-Paraffin, Peptide ELISA Detection limit 1:8000
Application Notes	Western blot: In transfected HEK293 transiently expressing Human SLAMF8 (myc and DYKDDDDK tagged), a band of approx. 45kDa is observed. No bands are observed in mock-transfected HEK293 and the same band is observed using anti-myc antibody. IHC: Paraffin embedded Human Small Intestine.

Images

Western Blot: BLAME/SLAMF8 Antibody [NBP2-26110] - HEK293 lysate (10 ug protein in RIPA buffer) overexpressing Human SLAMF8 with C-terminal MYC tag probed with NBP2-26110 (1 ug/ml) in Lane A and probed with anti-MYC Tag (1/1000) in lane C. Mock-transfected HEK293 probed with NBP2-26110 (1 ug/ml) in Lane B. Primary incubations were for 1 hour. Detected by chemiluminescence.



Immunohistochemistry-Paraffin: BLAME/SLAMF8 Antibody [NBP2-26110] - 5ug/ml staining of paraffin embedded Human Small Intestine. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.	
(a,b) Knockdown of NINJ2 significantly abolished SLAMF8-induced oxidative stress, reduced ROS levels (DCF and MitoSOX Red), and decreased NOX2 and NOX4 expression in Aβ1-42-treated SH-SY5Y cells. (c) Similarly, knockdown of NINJ2 significantly reduced the SLAMF8-treated neuroinflammation in LPS-treated HMC3 cells. (d) In SLAMF8-stably overexpressing AD cell models, transient knockdown of NINJ2 with siNINJ2 for 48 h significantly abolished SLAMF8-induced p65 phosphorylation in the TLR4/NF-κB signaling pathway. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey's post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. "*" indicates p ≤ 0.05, and "**" indicates p ≤ 0.01.. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.	
(a) The overexpression of SLAMF8 in AD cell models increased the levels of TLR4/NF-κB signaling-related markers (TLR4, p-IκBα/IκBα ratio) and the phospho-p65/p65 ratio, as confirmed by Western blot. Quantification of the Western blot results was performed and normalized against β-actin (n = 3) (a1). (b) Conversely, knockdown of SLAMF8 produced the opposite effect and the data were quantified and normalized to β-actin (n = 3). (b1) The TLR4/NF-κB signaling inhibitor TAK-242 suppressed TLR4 expression (c,c1) and mitigated the increase in ROS (d,e) and neuroinflammation (f) caused by SLAMF8 overexpression in AD cell models. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey's post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. "*" indicates p ≤ 0.05, and "**" indicates p ≤ 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.	

(a,b) Knockdown of NINJ2 significantly abolished SLAMF8-induced oxidative stress, reduced ROS levels (DCF and MitoSOX Red), and decreased NOX2 and NOX4 expression in Aβ1-42-treated SH-SY5Y cells. (c) Similarly, knockdown of NINJ2 significantly reduced the SLAMF8-treated neuroinflammation in LPS-treated HMC3 cells. (d) In SLAMF8-stably overexpressing AD cell models, transient knockdown of NINJ2 with siNINJ2 for 48 h significantly abolished SLAMF8-induced p65 phosphorylation in the TLR4/NF-κB signaling pathway. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey's post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. "*" indicates $p \leq 0.05$, and "**" indicates $p \leq 0.01$.. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



(a) The overexpression of SLAMF8 in AD cell models increased the levels of TLR4/NF-κB signaling-related markers (TLR4, p-IκBα/IκBα ratio) and the phospho-p65/p65 ratio, as confirmed by Western blot. Quantification of the Western blot results was performed and normalized against β-actin (n = 3) (a1). (b) Conversely, knockdown of SLAMF8 produced the opposite effect and the data were quantified and normalized to β-actin (n = 3). (b1) The TLR4/NF-κB signaling inhibitor TAK-242 suppressed TLR4 expression (c,c1) and mitigated the increase in ROS (d,e) and neuroinflammation (f) caused by SLAMF8 overexpression in AD cell models. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey's post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. "*" indicates $p \leq 0.05$, and "**" indicates $p \leq 0.01$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



(a) The overexpression of SLAMF8 in AD cell models increased the levels of TLR4/NF-κB signaling-related markers (TLR4, p-IκBα/IκBα ratio) and the phospho-p65/p65 ratio, as confirmed by Western blot. Quantification of the Western blot results was performed and normalized against β-actin (n = 3) (a1). (b) Conversely, knockdown of SLAMF8 produced the opposite effect and the data were quantified and normalized to β-actin (n = 3). (b1) The TLR4/NF-κB signaling inhibitor TAK-242 suppressed TLR4 expression (c,c1) and mitigated the increase in ROS (d,e) and neuroinflammation (f) caused by SLAMF8 overexpression in AD cell models. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey's post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. "*" indicates $p \leq 0.05$, and "**" indicates $p \leq 0.01$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Davila S, Froeling FE, Tan A et al. New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun 2010-04-01 [PMID: 20237496]

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-26110

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF017	Rabbit anti-Goat IgG Secondary Antibody [HRP (Horseradish Peroxidase)]
HAF109	Donkey anti-Goat IgG Secondary Antibody [HRP (Horseradish Peroxidase)]
NB410-28088-1mg	Goat IgG Isotype Control

Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-26110

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications